

**February 11, 2023**

**BSE Limited**

P. J. Towers,  
Dalal Street,  
Mumbai- 400 001  
**Scrip Code-540025**

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (E) Mumbai- 400 051  
**Trading Symbol-ADVENZYMES**

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations – merger by and between two step-down wholly owned subsidiaries, Dynamic Enzymes, Inc. USA and Advanced Supplementary Technologies Corporation, USA**

**Ref: ISIN: INE837H01020**

We hereby inform that the Board of Directors of the Company at its said meeting held on February 11, 2023 *inter alia*, took note of the following:

Approval of the Board of respective wholly owned subsidiaries i.e. Dynamic Enzymes, Inc., USA (“DE”) and Advanced Supplementary Technologies Corporation, USA (“AST”) regarding the proposed merger of DE and AST. DE and AST are direct wholly owned subsidiaries of Advanced Enzymes USA Inc. (“AEU”) and AEU is a direct wholly owned subsidiary of Advanced Enzyme Technologies Limited (“AETL”).

Pursuant to the approval of the respective Boards’ as mentioned above, DE will be merged with and into AST and consequently DE will cease to exist.

Details as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI circular No. CIR/CFD/CMD/4/2015 dated 9<sup>th</sup> September, 2015 are provided as an Annexure I.

This intimation is also being uploaded on the website of the Company i.e. [www.advancedenzymes.com](http://www.advancedenzymes.com). This is for your information and for public at large.

Thanking you,  
Yours faithfully,

**For Advanced Enzyme Technologies Limited**

**Sanjay Basantani**  
**Company Secretary and Head – Legal**

Encl.: As above

**Annexure I:**

Sr. No.	Particulars	Status / Remarks
a)	Name of the entity (ies) forming part of the <del>amalgamation</del> / merger, details in brief such as, size, turnover etc.	Merger between step-down wholly owned subsidiaries (overseas subsidiaries) of Advanced Enzyme Technologies Limited ("AETL"). Dynamic Enzymes, Inc., USA ("DE") – transferor. Gross sales as on March 31, 2022: USD 5.44 million; Advanced Supplementary Technologies Corporation, USA ("AST") – transferee. Gross sales as on March 31, 2022: USD 0.25 million
b)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	The merger is between two step-down wholly owned overseas subsidiaries (DE and AST as mentioned above) and AETL is not a party to the said merger.
c)	Area of business of the entity(ies)	DE: owned & branded Supplements for Retail business model. AST: owned & branded Supplements for Nutraceutical Applications
d)	Rationale for <del>amalgamation</del> /merger	Simplification of overall corporate structure, operational synergy and to align the resources (DE and AST represent that the merged entity will overall be more efficient without any increase in overall liability to either entity)
e)	In case of cash consideration – amount or otherwise share exchange ratio	Not applicable as merger is between DE and AST, both of which are wholly owned subsidiaries of Advanced Enzymes, USA ("AEU"). AEU is a wholly owned subsidiary of AETL
f)	Brief details of change in shareholding pattern (if any) of listed entity	Not applicable, as neither DE nor AST is a listed entity.

\*\*\*\*\*